A WEAK HUMAN MLR LOCUS MAPPING AT THE RIGHT OF A CROSSING‐OVER BETWEEN <i>HLA‐D, Bf</i> AND <i>GLO</i>

Mawas, Claude; Charmot, Dominique; Sivy, M.; Mercier, Pierre; North, M. L.; Hauptmann, G.

doi:10.1111/j.1744-313x.1978.tb00667.x

Cited by 56 publications

(25 citation statements)

References 29 publications

(13 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Definitive Assignment of the HAfi Gene(s) to the SB Region. Previous family studies were reported to show recombination between SB and DR (3)(4)(5)(6)(7)(8). In family Fa(3), a recombination divided the HLA-D region into two subregions, a Fig.…”

Section: Pst T Trpnacg Rkagctk Egcggccteaagap0agtactggpcagccagaagacatmentioning

confidence: 95%

“…The study of recombinant families in which positive MLR was detected between cells of genotypically DR,DC/MT-identical individuals allowed the division of the D region, between DR and GLO, into two subregions. These subregions were separated by recombination into a telomericregion coding for the DR and DC/ MT antigens and a centromeric region coding for a new segregant series called SB (3)(4)(5)(6)(7). Further analysis of informative.…”

Section: And 2)mentioning

confidence: 99%

See 1 more Smart Citation

Genetic mapping of a human class II antigen beta-chain cDNA clone to the SB region of the HLA complex.

Roux-Dosseto¹,

Auffray²,

Lillie³

et al. 1983

Proc. Natl. Acad. Sci. U.S.A.

100

View full text Add to dashboard Cite

A class II antigen (3-chain cDNA clone was isolated from a human B-cell cDNA library by using as a. probe the murine l-A13 gene. This cDNA clone, pHAI3, was shown to be distinct from theDCI3-and DR(3-related loci by DNA sequence analysis, thus suggesting that it might correspond to a third poly. morphic human class H locus, SB, which encodes secondary B-cell antigens. Genetic mapping of this (-chain cDNA clone to the SB region was performed by the blot hybridization procedure. We showed that (i) within panels of HLA-DR homozygous human Bcell lines and of unrelated individuals who have been typed for HLA antigens, differential mobility of DNA fragments segregated with distinct SB genotypes; (ii) y-ray-induced deletion mutants that have lost the expression of DR or DC/MT antigens but maintain SB expression preserved a pattern consistent with (a) their SB phenotype and (b) the genetic independence of the SB locus with respect to DR and DC/MT; and (iii) within an informative family, two siblings differing only for one allele at the SB locus (because of the occurrence of an internal recombination between DR and GLO) and otherwise HLA identical exhibited a restriction enzyme polymorphism linked to.the SB locus. Therefore, all available data are compatible with identity between HA.8 and SB(. In man, the highly polymorphic HLA-D region of the major histocompatibility complex (MHC), whose products have been primarily detected on B lymphocytes and macrophages, controls the major part of the proliferative response in mixed lymphocyte reaction (MLR). Serological as well as cellular reagents allowed the identification of two sets of molecular entities that display similar function and tissue distribution to HLA-D products. These antigens, named DR and DC, have been separated and are each composed of two noncovalently associated subunits, a heavy (a) and a light ((3) chain.. DR and DC are the structural equivalents of murine I-E and I-A antigens, respectively. Among the other serologically defined specificities is the MT series found in strong linkage disequilibrium with HLA-DR. Its molecular relationship to the DR and DC antigens is not well defined,.but MT1 has been shown to be identical to DC1 (for review, see refs. 1 and 2).Lymphocytes from individuals that type identically for all known HLA antigens, including DR and DC/MT, have been found to be capable of reciprocal MLR, suggesting the existence .of at least one additional MLR locus. The study of recombinant families in which positive MLR was detected between cells of genotypically DR,DC/MT-identical individuals allowed the division of the D region, between DR and GLO, into two subregions. These subregions were separated by recombination into a telomericregion coding for the DR and DC/ MT antigens and a centromeric region coding for a new segregant series called SB (3-7). Further analysis of informative. recombinant families (8) as well as y-ray-induced deletion mutants that have lost DR and DC/MT expression but maintained the SB expression (9, 10) clearly esta...

show abstract

Section: Pst T Trpnacg Rkagctk Egcggccteaagap0agtactggpcagccagaagacatmentioning

confidence: 95%

Section: And 2)mentioning

confidence: 99%

Genetic mapping of a human class II antigen beta-chain cDNA clone to the SB region of the HLA complex.

Roux-Dosseto¹,

Auffray²,

Lillie³

et al. 1983

Proc. Natl. Acad. Sci. U.S.A.

100

View full text Add to dashboard Cite

show abstract

“…The DP locus of the HLA class II system was first described in 1978 as a target of alloreactive T-cell responses identified in secondary mixed lymphocyte cultures. 2 Due to the scarce availability of specific antisera, the gene products of the HLA-DP locus remained poorly characterized for many years. Only the advent of molecular biology techniques for HLA typing allowed unraveling the full degree of HLA-DP polymorphism, with 20 and 106 HLA-DPA1 and DPB1 alleles, respectively, described to date.…”

Section: Introductionmentioning

confidence: 99%

A T-cell epitope encoded by a subset of HLA-DPB1 alleles determines nonpermissive mismatches for hematologic stem cell transplantation

Zino¹,

Frumento²,

Marktel³

et al. 2003

Blood

209

262

View full text Add to dashboard Cite

and *4501, but not other alleles. Based on these findings, we developed an algorithm for prediction of nonpermissive HLA-DPB1 mismatches. Retrospective evaluation of 118 transplantations showed that the presence of nonpermissive HLA-DPB1 mismatches was correlated with significantly increased hazards of acute grade II to IV graftversus-host disease (HR ‫؍‬ 1.87, P ‫؍‬ .046) and transplantation-related mortality (HR ‫؍‬ 2.69, P ‫؍‬ .027) but not relapse (HR ‫؍‬ 0.98, P ‫؍‬ .939), as compared with the permissive group. There was also a marked but statistically not significant increase in the hazards of overall mortality (HR ‫؍‬ 1.64, P ‫؍‬ .1). These data suggest that biologic characterization of in vivo alloreactivity can be a tool for definition of clinically relevant nonpermissive HLA mismatches for unrelated HSC transplantation.

show abstract

“…The replacement of leuko-agglutination by lymphocytotoxicity tests in 1964 [67] and the systematic analysis of antibodies formed in pregnancy have brought substantial progress in clinically applied HLA typing for class I antigens. The application of the PLT allowed the discrimination of six antigens HLA-DPwl -DPw6 [19,20]. In the late 1970s, sera from multiparous women were obtained with similar specificities as the MLC for HLA-D.…”

Section: Hla Typing Methodsmentioning

confidence: 99%

“…This locus became known as HLA-D. With the help of homozygous typing cells used in the MLC several alleles of this locus were defined [16]. The existence of a third HLA class II locus -named SB (now HLA-DP) -was demonstrated by the use of a secondary MLC, the primed lymphocyte test (PLT) [19,20]. These antigens were designated HLA-D related or HLA-DR. Further analysis of more sera succeeded in the discovery of the MB gene (now HLA-DQ) [18].…”

Section: History Of Hlamentioning

confidence: 99%

New Diagnostic Methods in Oncology and Hematology

Huhn¹

1998

View full text Add to dashboard Cite

A WEAK HUMAN MLR LOCUS MAPPING AT THE RIGHT OF A CROSSING‐OVER BETWEEN HLA‐D, Bf AND GLO

Cited by 56 publications

References 29 publications

Genetic mapping of a human class II antigen beta-chain cDNA clone to the SB region of the HLA complex.

Genetic mapping of a human class II antigen beta-chain cDNA clone to the SB region of the HLA complex.

A T-cell epitope encoded by a subset of HLA-DPB1 alleles determines nonpermissive mismatches for hematologic stem cell transplantation

New Diagnostic Methods in Oncology and Hematology

Contact Info

Product

Resources

About